Greenwich LifeSciences price target raised to $39 from $38 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Greenwich LifeSciences (GLSI) to $39 from $38 and keeps a Buy rating on the shares. The company earlier this month reported positive immune response data from the ongoing Phase 3 FLAMINGO-01 trial of GLSI-100 in breast cancer, the analyst tells investors in a research note.